# Pharmacokinetics, Pharmacodynamics and Safety of SHR4640 in Patients With Hepatic Impairment

> **NCT04305392** · PHASE1 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 24 (actual)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** SHR4640

## Key facts

- **NCT ID:** NCT04305392
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-04
- **Primary completion:** 2022-12
- **Final completion:** 2022-12
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2022-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04305392

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04305392, "Pharmacokinetics, Pharmacodynamics and Safety of SHR4640 in Patients With Hepatic Impairment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04305392. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*